Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

Jun 3 2011

iBio, Inc. (NYSE AMEX: IBIO) today announced positive interim results from a Phase 1 clinical trial of an iBioLaunch™ platform-produced subunit vaccine directed against Influenza A/California/04/09 (H1N1). The vaccine demonstrated strong induction of dose correlated immune responses, with or without adjuvant, as assessed by virus microneutralization antibody assays and hemagglutination inhibition (HAI) responses. The vaccine was safe and well tolerated at all doses when administered with and without adjuvant.

"These expected positive results are an important confirmation of the utility of the iBioLaunch platform, not only for rapid response to infectious disease challenges such as influenza, but also as a preferred approach to a broad range of vaccine and therapeutic products," said Robert Kay, iBio's Chairman and Chief Executive Officer.

Source: iBio, Inc.